Specialty medicines Product information: ZEJULA product monograph (PDF - 553 KB) Health Product Risk Communication: 16 February 2023 – Important Safety Information on ZEJULA (niraparib) - Update on the Maintenance Treatment in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in the Second or Later Line Setting (PDF - 129 KB)
